{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:06:54Z","timestamp":1788174414636,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,23]]},"DOI":"10.7759\/cureus.34088","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T15:59:25Z","timestamp":1674489565000},"source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and Risk Factors Associated With Inflammatory Bowel Disease in Patients Using Proton-Pump Inhibitors: A Population-Based Study"],"prefix":"10.7759","author":[{"given":"Somtochukwu","family":"Onwuzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Boustany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Khaled Abou Zeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Hitawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Almomani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidera","family":"Onwuzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Favour","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"Mascarenhas Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidera","family":"Ndubueze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Asaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima JJ","year":"2021","unstructured":"Lima JJ, Thomas CD, Barbarino J, et al.. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2021, 109:1417-23. 10.1002\/cpt.2015","journal-title":"Clin Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato C","year":"2016","unstructured":"Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016, 14:179. 10.1186\/s12916-016-0718-z","journal-title":"BMC Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2020.09.015","article-title":"National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017","author":"Mishuk AU","year":"2020","unstructured":"Mishuk AU, Chen L, Gaillard P, Westrick S, Hansen RA, Qian J. National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017. J Am Pharm Assoc (2003). 2020, 10.1016\/j.japh.2020.09.015","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009","volume":"8","author":"Rotman SR","year":"2013","unstructured":"Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009. PLoS One. 2013, 8:e56060. 10.1371\/journal.pone.0056060","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-2259","article-title":"Proton pump inhibitors use and risk of inflammatory bowel diseases: a meta-analysis of observational studies","volume":"95","author":"Shastri SA","year":"2022","unstructured":"Shastri SA, Kantamneni R, Rashid M, et al.. Proton pump inhibitors use and risk of inflammatory bowel diseases: a meta-analysis of observational studies. Med Pharm Rep. 2022, 95:357-69. 10.15386\/mpr-2259","journal-title":"Med Pharm Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong BK","year":"2019","unstructured":"Thong BK, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019, 16:1571. 10.3390\/ijerph16091571","journal-title":"Int J Environ Res Public Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.462","article-title":"Proton pump inhibitors and hypomagnesemia: a rare but serious complication","volume":"83","author":"Perazella MA","year":"2013","unstructured":"Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013, 83:553-6. 10.1038\/ki.2012.462","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-24.6.489","article-title":"Proton pump inhibitors, H(2) blocker use, and risk of inflammatory bowel disease in children","volume":"24","author":"Schwartz NR","year":"2019","unstructured":"Schwartz NR, Hutfless S, Herrinton LJ, et al.. Proton pump inhibitors, H(2) blocker use, and risk of inflammatory bowel disease in children. J Pediatr Pharmacol Ther. 2019, 24:489-96. 10.5863\/1551-6776-24.6.489","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.giec.2019.12.005","article-title":"Proton pump inhibitors: the good, bad, and ugly","volume":"30","author":"Schnoll-Sussman F","year":"2020","unstructured":"Schnoll-Sussman F, Niec R, Katz PO. Proton pump inhibitors: the good, bad, and ugly. Gastrointest Endosc Clin N Am. 2020, 30:239-51. 10.1016\/j.giec.2019.12.005","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i24.2667","article-title":"Rebuilding trust in proton pump inhibitor therapy","volume":"28","author":"Turshudzhyan A","year":"2022","unstructured":"Turshudzhyan A, Samuel S, Tawfik A, Tadros M. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol. 2022, 28:2667-79. 10.3748\/wjg.v28.i24.2667","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2014.03.019","article-title":"Rising rates of proton pump inhibitor prescribing in US emergency departments","volume":"32","author":"Mazer-Amirshahi M","year":"2014","unstructured":"Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med. 2014, 32:618-22. 10.1016\/j.ajem.2014.03.019","journal-title":"Am J Emerg Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.08.005","article-title":"Regular use of proton pump inhibitor and the risk of inflammatory bowel disease: pooled analysis of three prospective cohorts","volume":"161","author":"Xia B","year":"2021","unstructured":"Xia B, Yang M, Nguyen LH, et al.. Regular use of proton pump inhibitor and the risk of inflammatory bowel disease: pooled analysis of three prospective cohorts. Gastroenterology. 2021, 161:1842-1852.e10. 10.1053\/j.gastro.2021.08.005","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/8755122515575177","article-title":"Review of proton pump inhibitor overuse in the US veteran population","volume":"31","author":"Metaxas ES","year":"2015","unstructured":"Metaxas ES, Bain KT. Review of proton pump inhibitor overuse in the US veteran population. J Pharm Technol. 2015, 31:167-76. 10.1177\/8755122515575177","journal-title":"J Pharm Technol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321609","article-title":"The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies","volume":"70","author":"Lu TX","year":"2021","unstructured":"Lu TX, Dapas M, Lin E, Peters T, Sakuraba A. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut. 2021, 70:2076-84. 10.1136\/gutjnl-2020-321609","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4065\/81.11.1462","article-title":"Smoking and inflammatory bowel disease: a meta-analysis","volume":"81","author":"Mahid SS","year":"2006","unstructured":"Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006, 81:1462-71. 10.4065\/81.11.1462","journal-title":"Mayo Clin Proc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161202","article-title":"Risk of ulcerative colitis among former and current cigarette smokers","volume":"316","author":"Boyko EJ","year":"1987","unstructured":"Boyko EJ, Koepsell TD, Perera DR, Inui TS. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med. 1987, 316:707-10. 10.1056\/NEJM198703193161202","journal-title":"N Engl J Med"},{"key":"ref17","article-title":"Coffee and alcohol use and the risk of ulcerative colitis","volume":"84","author":"Boyko EJ","year":"1989","unstructured":"Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS. Coffee and alcohol use and the risk of ulcerative colitis. Am J Gastroenterol. 1989, 84:530-4.","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/134570-prevalence-and-risk-factors-associated-with-inflammatory-bowel-disease-in-patients-using-proton-pump-inhibitors-a-population-based-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:29Z","timestamp":1707508589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/134570-prevalence-and-risk-factors-associated-with-inflammatory-bowel-disease-in-patients-using-proton-pump-inhibitors-a-population-based-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.34088","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,23]]}}}